Clinical Trials
2.9k
Active:467
Completed:1187
Trial Phases
6 Phases
Early Phase 1:76
Phase 1:721
Phase 2:1004
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2418 trials with phase data)β’ Click on a phase to view related trials
Phase 2
1004 (41.5%)Phase 1
721 (29.8%)Not Applicable
486 (20.1%)Phase 3
102 (4.2%)Early Phase 1
76 (3.1%)Phase 4
29 (1.2%)A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT07193550
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Not Applicable
Not yet recruiting
- Conditions
- Acute Lymphoblastic LeukemiaPhase 2 StudyBlinatumomab
- Interventions
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT07192237
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Quality of Life in Breast Cancer Survivors Who Were Pregnant During Their Cancer Treatment
Not yet recruiting
- Conditions
- Breast Cancer SurvivorPregnant WomenQuality of Lifte
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT07191496
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Not Applicable
Not yet recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT07187778
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Not Applicable
Not yet recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT07187869
- Prev
- 1
- 2
- 3
- 4
- 5
- 584
- Next
News
No news found